Financials AddLife AB

Equities

ALIF B

SE0014401378

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 11:43:46 19/06/2024 BST 5-day change 1st Jan Change
124.1 SEK -1.90% Intraday chart for AddLife AB -1.66% +13.71%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 46,512 13,229 13,331 15,416 - -
Enterprise Value (EV) 1 50,269 13,229 18,523 19,985 19,278 19,025
P/E ratio 63.5 x 27.5 x 70.1 x 64.1 x 35 x 26.5 x
Yield 0.52% - 0.46% 0.55% 1.08% 1.51%
Capitalization / Revenue 5.82 x 1.46 x 1.38 x 1.53 x 1.43 x 1.31 x
EV / Revenue 6.29 x 1.46 x 1.91 x 1.98 x 1.79 x 1.62 x
EV / EBITDA 34.1 x 8.65 x 12.3 x 13.5 x 11.9 x 10.5 x
EV / FCF 57.4 x - 40.6 x 26.2 x 23.9 x 20.7 x
FCF Yield 1.74% - 2.46% 3.82% 4.19% 4.84%
Price to Book 10.8 x - 2.69 x 3 x 2.81 x 2.6 x
Nbr of stocks (in thousands) 121,952 121,812 121,857 121,864 - -
Reference price 2 381.4 108.6 109.4 126.5 126.5 126.5
Announcement Date 04/02/22 02/02/23 02/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 7,993 9,084 9,685 10,109 10,788 11,735
EBITDA 1 1,474 1,530 1,504 1,485 1,620 1,814
EBIT 1 996 808 585 693.5 820.9 1,012
Operating Margin 12.46% 8.89% 6.04% 6.86% 7.61% 8.62%
Earnings before Tax (EBT) 1 927 602 339 370.7 594.1 764.8
Net income 1 719 480 190 240.3 440.1 581.2
Net margin 9% 5.28% 1.96% 2.38% 4.08% 4.95%
EPS 2 6.010 3.950 1.560 1.972 3.613 4.770
Free Cash Flow 1 876 - 456 764 808 920
FCF margin 10.96% - 4.71% 7.56% 7.49% 7.84%
FCF Conversion (EBITDA) 59.43% - 30.32% 51.45% 49.88% 50.71%
FCF Conversion (Net income) 121.84% - 240% 317.88% 183.6% 158.29%
Dividend per Share 2 2.000 - 0.5000 0.6969 1.363 1.908
Announcement Date 04/02/22 02/02/23 02/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 2,131 2,579 2,457 2,365 2,319 2,544 2,570 2,517 2,374 2,647
EBITDA 1 388 509 448 342 332 - 384 380 331 401
EBIT 1 245 338 258 136 132 - 186 182 142 200
Operating Margin 11.5% 13.11% 10.5% 5.75% 5.69% - 7.24% 7.23% 5.98% 7.56%
Earnings before Tax (EBT) 1 - 289 206 70 61 2 100 111 69 128
Net income 1 178 225 174 33 26 -41 62 71 44 82
Net margin 8.35% 8.72% 7.08% 1.4% 1.12% -1.61% 2.41% 2.82% 1.85% 3.1%
EPS 2 1.450 - 1.430 0.2700 0.2000 -0.3400 0.5200 0.5800 0.3600 0.6700
Dividend per Share - - - - - - - - - -
Announcement Date 04/02/22 28/04/22 26/04/23 14/07/23 26/10/23 02/02/24 24/04/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 3,757 - 5,192 4,569 3,862 3,609
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.549 x - 3.452 x 3.077 x 2.384 x 1.989 x
Free Cash Flow 1 876 - 456 764 808 920
ROE (net income / shareholders' equity) 22% - 4% 4.74% 8.26% 10.2%
ROA (Net income/ Total Assets) - - 1.47% - - -
Assets 1 - - 12,901 - - -
Book Value Per Share 2 35.20 - 40.70 42.20 45.10 48.60
Cash Flow per Share 8.460 - - - - -
Capex 1 134 - 286 220 224 264
Capex / Sales 1.68% - 2.95% 2.18% 2.08% 2.25%
Announcement Date 04/02/22 02/02/23 02/02/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
126.5 SEK
Average target price
142.5 SEK
Spread / Average Target
+12.65%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW